New AI reads CT scans to predict which esophageal cancers vanish after treatment
NCT ID NCT07181850
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a computer model could predict if esophageal cancer completely disappears after chemo-immunotherapy. Researchers reviewed medical records and CT scans from 363 patients who received standard treatment before surgery. The AI combined clinical data, radiomics, and deep learning to predict which patients had no cancer left at surgery. If validated, this tool could help personalize treatment and avoid unnecessary surgeries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab with paclitaxel and cisplatin or carboplatin
What this could lead to
If successful, this AI tool could help doctors quickly identify which patients benefit from chemo-immunotherapy before surgery, avoiding unnecessary treatments for non-responders.
What could go wrong
This is a retrospective observational study, not a controlled trial. The AI model needs prospective validation and may not work in different hospitals or populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University
Huai'an, Jiangsu, 223000, China